



A brief overview of Global Life Science Ventures

Global Life Science Ventures (GLSV) is a leading, independent venture capital fund focusing exclusively on the life sciences. It is dedicated to supporting early-stage groups originating from universities, scientific institutions or industry, but will also invest in selected later-stage companies, including buy-outs. For this purpose, GLSV provides finance, advice and access to expertise and networks. The group currently advises and manages funds greater than EUR 200 million. With two locations in Germany and Switzerland, GLSV acts as one team with a global perspective. The GLSV portfolio includes companies active in many areas of the life sciences ranging from biopharmaceuticals, cancer, immunology, vaccines and genomics to diagnostics, medical devices and healthcare services.

An industry-born team. GLSV has established a strong investment team of 5 professionals including pharma managers and bio-/medtech entrepreneurs and a network of advisors with many years of complementary experience in the life science industry. The expertise of the team ranges from industrial experience in molecular biology, immunology, diagnostics, pharmaceuticals and medical devices to marketing, senior level strategic business development, finance and administration.

Proven track record. Over the years, GLSV has achieved a sound track record through discerning investments in high-potential companies. After registration of the first fund **GLS I** in 1996, the available capital of Euro 66 million has been invested in first and follow-on financing rounds of 18 companies from primarily Germany and also the USA. In 2002, GLSV closed its second fund **GLSV II** raising Euro 143 million. So far, GLSV II has invested throughout Europe and the USA in 20 companies, including two spin-offs.

Pro-active syndicate partner. GLSV offers its investees access to the capital, experience and networks of a group of international venture capitalists from Europe and the USA that invest in the life sciences on a global scale. Syndicate partnerships are made with funds whose investment criteria and philosophy match those of GLSV.

Top quartile performance. According to Cambridge Associates data, GLSV II is a European top performer both in terms of net IRR and distributions to investors. One third of all portfolio companies have already achieved a public listing, respectively an exit through trade sale or M&A.

GLSV III shall finance further promising companies in the life sciences that address significant unmet medical needs. The new investments will again meet GLSV's established criteria for a balanced portfolio across different industry sectors, early to late development stages and geography.

January 2008

Switzerland

GLSV AG
Postplatz 1, P.O. 626
CH – 6301 Zug
Tel. +41 (0)41 727 19 40
Fax +41 (0)41 727 19 45

Germany

GLSV GmbH
Von-der-Tann-Str. 3
D – 80539 München
Tel. +49 (0)89 288 151 0
Fax +49 (0)89 288 151 30

www.glsv-vc.com mailbox@glsv-vc.com

Industry-born team – Proven track record – Global perspective